NCT06138275 - Elranatamab in R/R Multiple Myeloma | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

March 8, 2024

Primary Completion Date

December 1, 2025

Study Completion Date

December 1, 2028

Conditions

Refractory Multiple MyelomaRelapse Multiple MyelomaMultiple Myeloma

Interventions

DRUG

Elranatamab

subcutaneous (under the skin) injection

Trial Locations (3)

RECRUITING

Massachusetts General Hospital, Boston

RECRUITING

Dana-Farber Cancer Institute, Boston

RECRUITING

Beth-Israel Deaconess Medical Center, Boston